Login
CODEXIS, INC. logo

CODEXIS, INC.

codexis.com

What Do They Do?

Develops and sells engineered enzymes and manufacturing tools and services for pharmaceutical companies and drug developers, including enzymes for small-molecule drug production and processes for making RNA interference therapeutics.

How Do They Make Money?

Research and development work brings in more revenue: customers pay project-team fees as the work is performed, sometimes with upfront or milestone payments. Product customers pay for enzymes and other products when shipped or, for custom-made orders, as they are made.

revenue
SegmentShareRevenue
Product revenue
Sold outright

37%
FY2022: 84%
Research and development revenue
Recurring

63%
FY2022: 16%

Who Are Their Customers?

Pharmaceutical manufacturers work with Codexis to develop and buy enzymes for small-molecule drug production; RNAi drug sponsors work with the company on development and manufacturing-process services.

Customers above 10% of revenue, FY2025
of revenue from one customer

Do Revenues Turn Into Profits?

No. It lost $44M in FY2025.

Operating income, FY2025
−59% of revenue
▲ +29% (Loss) vs FY2024 (−$58.5M, −99%)
Net income, FY2025
−62% of revenue
▲ +33% (Loss) vs FY2024 (−$65.3M, −110%)
Free cash flow, FY2025
−34% of revenue
▲ +56% (Loss) vs FY2024 (−$53.7M, −91%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +124%
vs $8.6M in Q3 FY2025
Net income
▲ +59% (Loss)
vs −$19.6M in Q3 FY2025
Research and development revenue share of revenue vs 20.9% in Q3 FY2025
  • Nov 12, 2026 Reiterated 2026 revenue guidance Full-year revenue is expected to be $72 million to $76 million; the gross-margin estimate increased to the low 70% range.

Shrinking. Revenue fell 33% in 4 years, from $104.8M in FY2021 to $70.4M in FY2025, about 9% a year.

From therapies to manufacturing The older report described a biotherapeutics pipeline and life-sciences enzymes; the latest centers on therapeutic manufacturing, including RNAi manufacturing and pharma biocatalysis, and says investment in biotherapeutics was discontinued.

Revenue over time
Product revenue Research and development revenue
$200M$100M$0

Who Do They Compete With?

Competes with Agilent Technologies, EnPlusOne Biosciences, Solvias, BASF, Johnson-Matthey, Takasago International, DSM Firmenich, Cambrex, Lonza, WuXi STA, Almac Group, Ginkgo Bioworks, BRAIN, evoxx technologies, c-LEcta, Enzymicals, Enzymaster, Biomatter Designs, and Arzeda

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support